-
EP4522173
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4522173
| EP4522173 - METHODS AND COMPOSITIONS COMPRISING A SHP2 INHIBITOR AND A PD-L1 BINDING ANTAGONIST [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.02.2025 Database last updated on 09.04.2026 | |
| Former | The international publication has been made Status updated on 17.11.2023 | ||
| Former | unknown Status updated on 16.06.2023 | Most recent event Tooltip | 18.03.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states Genentech Inc. 1 DNA Way South San Francisco, California 94080-4990 / US | [2025/12] | Inventor(s) | 01 /
ENG-WONG, Jennifer San Francisco, California 94080-4990 / US | 02 /
LARROCHA, Pablo Saenz-Lopez San Francisco, California 94080-4990 / US | 03 /
LAU, Jeffrey San Francisco, California 94080-4990 / US | 04 /
SODIR, Nicole San Francisco, California 94080-4990 / US | 05 /
ADAMKEWICZ, Joanne Irene San Francisco, California 94080-4990 / US | 06 /
MADDALO, Danilo San Francisco, California 94080-4990 / US | 07 /
MERCHANT, Mark Andrew San Francisco, California 94080-4990 / US | 08 /
PATHRIA, Gaurav San Francisco, California 94080-4990 / US | [2025/12] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2025/12] | Application number, filing date | 23729279.2 | 12.05.2023 | [2025/12] | WO2023US66920 | Priority number, date | US202263341361P | 12.05.2022 Original published format: US 202263341361 P | [2025/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023220703 | Date: | 16.11.2023 | Language: | EN | [2023/46] | Type: | A1 Application with search report | No.: | EP4522173 | Date: | 19.03.2025 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.11.2023 takes the place of the publication of the European patent application. | [2025/12] | Search report(s) | International search report - published on: | EP | 16.11.2023 | Classification | IPC: | A61K31/4985, A61K39/395, A61K45/06, A61P35/00 | [2025/12] | CPC: |
A61K31/4985 (EP,KR,US);
A61K39/395 (EP,KR);
A61K39/3955 (US);
A61K45/06 (EP,KR);
A61P35/00 (EP,KR,US);
C07K16/2827 (EP,KR);
A61K2039/505 (KR,US);
A61K2039/545 (EP,KR,US);
A61K2300/00 (KR);
| C-Set: |
A61K31/4985, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/12] | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN MIT EINEM SHP2-INHIBITOR UND EINEM PD-L1-BINDENDEN ANTAGONISTEN | [2025/12] | English: | METHODS AND COMPOSITIONS COMPRISING A SHP2 INHIBITOR AND A PD-L1 BINDING ANTAGONIST | [2025/12] | French: | MÉTHODES ET COMPOSITIONS COMPRENANT UN INHIBITEUR DE SHP2 ET UN ANTAGONISTE DE LIAISON À PD-L1 | [2025/12] | Entry into regional phase | 18.09.2024 | National basic fee paid | 18.09.2024 | Designation fee(s) paid | 18.09.2024 | Examination fee paid | Examination procedure | 18.09.2024 | Examination requested [2025/12] | 18.09.2024 | Date on which the examining division has become responsible | 19.06.2025 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 20.05.2025 | Renewal fee patent year 03 | 17.03.2026 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY] WO2021061706 (RELAY THERAPEUTICS INC et al.) | [Y] US2022127271 (WAN HUIXIN et al.) | [Y] WILLIAMS BRET ET AL: "Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors | Cancer Research | American Association for Cancer Research", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2022 APR 8-13, 13 April 2022 (2022-04-13), XP093074737, Retrieved from the Internet | [Y] AKINLEYE AKINTUNDE ET AL: "Immune checkpoint inhibitors of PD-L1 as cancer therapeutics", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 12, no. 1, 5 September 2019 (2019-09-05), XP055785954, Retrieved from the Internet DOI: http://dx.doi.org/10.1186/s13045-019-0779-5 | [XP] ANONYMOUS: "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors", 2 August 2022 (2022-08-02), XP093074356, Retrieved from the Internet | by applicant | WO2010077634 | US8217149 | WO2011066389 | US2013034559 | WO2007005874 | US2016108123 | WO2016000619 | WO2012145493 | US9205148 | WO2013181634 | WO2016061142 | US2018030138 | US2018037655 | JMED CHEM, vol. 63, 2020, pages 11368 - 11396 | EUR J MED GENET., vol. 58, no. 10, 2015, pages 509 - 25 | PHARMACOL RES, vol. 152, 2020, pages 104595 - 104605 | SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, J. WILEY & SONS | SAMBROOK ET AL.: "MOLECULAR CLONING, A LABORATORY MANUAL", 1989, COLD SPRINGS HARBOR PRESS | "Uniprot", Database accession no. Q9NZQ7-3 | KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH | "International Nonproprietary Names for Pharmaceutical Substances", PROPOSED INN: LIST 112, vol. 28, no. 4, 16 January 2015 (2015-01-16), pages 485 | ABBAS ET AL.: "Cellular and Mol. Immunology", 2000, W.B. SAUNDERS, CO. | CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 | MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745 | FORREST ET AL., CANCER RES, vol. 80, no. 22, 2020, pages 5089 - 97 |